Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility by Sud, A. (Amit) et al.
ARTICLE
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Several susceptibility loci for classical Hodgkin lymphoma have been reported. However,
much of the heritable risk is unknown. Here, we perform a meta-analysis of two existing
genome-wide association studies, a new genome-wide association study, and replication
totalling 5,314 cases and 16,749 controls. We identify risk loci for all classical Hodgkin
lymphoma at 6q22.33 (rs9482849, P= 1.52 × 10−8) and for nodular sclerosis Hodgkin lym-
phoma at 3q28 (rs4459895, P= 9.43 × 10−17), 6q23.3 (rs6928977, P= 4.62 × 10−11), 10p14
(rs3781093, P= 9.49 × 10−13), 13q34 (rs112998813, P= 4.58 × 10−8) and 16p13.13
(rs34972832, P= 2.12 × 10−8). Additionally, independent loci within the HLA region are
observed for nodular sclerosis Hodgkin lymphoma (rs9269081, HLA-DPB1*03:01, Val86 in
HLA-DRB1) and mixed cellularity Hodgkin lymphoma (rs1633096, rs13196329, Val86 in HLA-
DRB1). The new and established risk loci localise to areas of active chromatin and show an
over-representation of transcription factor binding for determinants of B-cell development and
immune response.
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C lassical Hodgkin lymphoma (cHL) is a lymphoid malig-nancy of germinal centre (GC) B-cell origin1, which ischaracterised by Hodgkin and Reed–Sternberg (HRS) cells
with a dominant background population of reactive inﬂammatory
cells1. Of the four major subtypes of cHL, nodular sclerosis
Hodgkin lymphoma (NSHL) and mixed cellularity Hodgkin lym-
phoma (MCHL) account for 65% and 20% of cHL, respectively2.
While Epstein–Barr virus (EBV) infection is causally associated with
a subset of cHL cases, proportionally higher in MCHL, no other
environmental factor has thus far been robustly linked to cHL risk3.
Evidence for inherited genetic inﬂuence on susceptibility to
cHL is provided by the familial risk and the high concordance
between monozygotic twins4, 5. A strong HLA association
for cHL risk is well established; however, our understanding of
cHL heritability has been transformed by recent genome-wide
association studies (GWAS), which have identiﬁed single-
nucleotide polymorphisms (SNPs) at seven non-HLA loci
inﬂuencing risk6–9. Although projections indicate that additional
risk variants for cHL can be discovered by GWAS10, the statistical
power of published studies is limited.
To gain a more comprehensive insight into cHL predisposition,
we performed a meta-analysis of two previous GWAS7, 8 and a
new GWAS, thereby more than doubling study power to discover
risk SNPs. With replication, our study has allowed us to identify
six new non-HLA risk loci. Additionally, by conducting region-
speciﬁc imputation we have deﬁned the speciﬁc HLA associations
underlying NSHL and MCHL risk.
Results
Association analysis. We analysed GWAS data from three
studies of European ancestry: a new GWAS from the UK
National Study of Hodgkin Lymphoma Genetics (NSHLG) and
two previously reported GWAS (Supplementary Table 1)7, 8.
After quality control the three studies provided SNP genotypes on
3,077 cases and 13,680 controls (Supplementary Tables 2, 3, 4;
Supplementary Fig. 1). To increase genomic resolution, we
imputed >10 million SNPs using the 1000 Genomes Project and
the UK10K data as reference11, 12. Quantile–quantile (Q–Q) plots
for SNPs with minor allele frequency (MAF)> 0.05% post
imputation did not show evidence of substantive over-dispersion
(λ= 1.03–1.09; Supplementary Fig. 2). An overview of the ana-
lysis strategy is outlined in Supplementary Fig. 3. Meta-analysing
the association test results from the three GWAS into a joint
discovery set, we calculated joint odds ratios and 95% conﬁdence
intervals for each SNP and associated per-allele P-value for all
cHL, NSHL and MCHL cases vs. controls (Supplementary Fig. 4).
In this analysis, associations for the established non-HLA risk loci
at 2p16.1, 3p24.1, 5q31.1, 6q23.3, 8q24.21, 10p14 and 19p13.3
were consistent in direction and magnitude of effect with pre-
viously reported studies (Supplementary Fig. 4; Supplementary
Table 5)6–8.
We sought validation of association SNPs with a P-value from
the meta-analysis under a ﬁxed-effects model at P< 1.0 × 10−7
and P< 1.0 × 10−6 for loci not previously associated with cHL and
NSHL risk, respectively, by genotyping two additional indepen-
dent series (Supplementary Table 1), totalling 2,237 cases and
3,069 controls (Table 1; Supplementary Table 6). Where the
strongest signal was provided by an imputed SNP, we conﬁrmed
the ﬁdelity of imputation by genotyping (Supplementary Table 7).
In the combined meta-analysis, we identiﬁed genome-wide
signiﬁcant associations for cHL (Table 1; Supplementary Tables 8
and 9), at 3q28 (rs4459895, P= 4.45 × 10−18), 6q22.33 (rs9482849,
P= 1.52 × 10−8), 6q23.3 (rs6928977, P= 1.24 × 10−10) and 10p14
Table 1 Summary results for newly identiﬁed risk loci
Nearest
genea
Risk allele
(frequency)
Discovery GWAS
meta-analysis
UK Replication 1 UK Replication 2 Meta-analysis
Position
(hg19, bp)
P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) I2
(%)
Phet
3q28,
rs4459895
LPP A (0.20) 187954414
cHL 4.16 × 10−10 1.27 (1.18–1.36) 6.85 × 10−9 1.44 (1.27–1.63) 0.02 1.26 (1.04–1.52) 4.45 × 10−18 1.30 (1.23–1.38) 13 0.33
NSHL 9.16 × 10−9 1.37 (1.23–1.53) 1.37 × 10−8 1.43 (1.26–1.62) 0.04 1.30 (1.02–1.66) 9.43 × 10−17 1.39 (1.28–1.50) 0 0.93
MCHL 0.92 1.04 (0.91–1.19) 0.98 1.00 (0.68–1.47) 0.55 1.04 (0.92–1.19) 0 0.82
6q22.33,
rs9482849
PTPRK C (0.17) 128288536
cHL 5.02 × 10−8 1.24 (1.15–1.35) 0.13 1.11 (0.97–1.27) 0.13 1.17 (0.95–1.43) 1.52 × 10−8 1.20 (1.13–1.28) 3 0.39
NSHL 2.91 × 10−6 1.32 (1.17–1.48) 0.17 1.10 (0.96–1.25) 0.20 1.19 (0.91–1.54) 4.13 × 10−6 1.21 (1.12–1.33) 10 0.35
MCHL 0.17 1.11 (0.96–1.28) 0.78 1.06 (0.70–1.61) 0.16 1.10 (0.96–1.26) 0 0.97
6q23.3,
rs6928977
AHI1 G (0.57) 135626348
cHL 1.66 × 10−8 1.18 (1.12–1.26) 0.01 1.14 (1.03–1.26) 0.05 1.16 (1.00–1.34) 1.24 × 10−10 1.17 (1.12–1.23) 0 0.85
NSHL 9.34 × 10−10 1.31 (1.20–1.42) 0.03 1.12 (1.01–1.24) 0.01 1.30 (1.06–1.58) 4.62 × 10−11 1.23 (1.16–1.31) 26 0.25
MCHL 0.24 1.06 (0.96–1.18) 0.69 1.06 (0.79–1.42) 0.22 1.06 (0.96–1.17) 0 0.22
10p14,
rs3781093
GATA3 T (0.88) 8101927
cHL 4.89 × 10−12 1.35 (1.23–1.47) 4.00 × 10−4 1.32 (1.25–1.44) 0.11 1.21 (0.96–1.52) 4.91 × 10−12 1.28 (1.19–1.37) 64 0.01
NSHL 9.16 × 10−12 1.53 (1.36–1.75) 2.00 × 10−4 1.44 (1.31–1.61) 0.64 0.92 (0.68–1.26) 9.49 × 10−13 1.39 (1.28–1.53) 61 0.06
MCHL 0.03 1.18 (1.02–1.36) 0.05 1.56 (1.02–2.40) 0.16 0.91 (0.79–1.04) 73 0.03
13q34,
rs112998813
UPF3A C (0.08) 115059729
cHL 3.63 × 10−3 1.19 (1.06–1.33) 0.03 1.23 (1.03–1.47) 0.43 1.12 (0.84–1.50) 2.70 × 10−4 1.19 (1.08–1.30) 13 0.32
NSHL 8.43 × 10−8 1.58 (1.34–1.88) 0.03 1.22 (1.02–1.47) 0.28 1.23 (0.85–1.78) 4.58 × 10−8 1.39 (1.23–1.56) 27 0.24
MCHL 0.92 0.99 (0.80–1.22) 0.27 1.35 (0.80–2.23) 0.75 1.03 (0.85–1.25) 0 0.56
16p13.13,
rs34972832
CLEC16A A (0.18) 11198938
cHL 1.45 × 10−4 1.15 (1.07–1.23) 6.34 × 10−3 1.18 (1.05–1.34) 0.10 1.17 (0.97–1.42) 8.03 × 10−7 1.16 (1.09–1.23) 6 0.37
NSHL 7.47 × 10−7 1.24 (1.15–1.34) 6.53 × 10−3 1.30 (1.17–1.45) 0.28 1.15 (0.89–1.50) 2.12 × 10−8 1.24 (1.15–1.34) 37 0.18
MCHL 0.65 0.97 (0.85–1.11) 0.91 1.02 (0.69–1.52) 0.70 0.98 (0.86–1.10) 0 0.94
The risk allele is the allele corresponding to the estimated odds ratio. Frequency of the risk allele is from the CEU population from 1000 Genomes Project
cHL classical Hodgkin lymphoma, NSHL nodular sclerosis Hodgkin lymphoma, MCHL mixed cellularity Hodgkin lymphoma, bp base pair, OR odds ratio, CI conﬁdence interval, I2 proportion of the total
variation due to heterogeneity
I2 value≥ 75% is considered to be characteristic of large heterogeneity
aNearest gene may not be the functional gene
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(rs3781093, P= 4.91 × 10−12), which were predominantly driven
by an association with NSHL. The rs6928977 association is
independent of the previously identiﬁed association at 6q23.3
marked by rs9402684 (Supplementary Table 5); respective
conditional P-values, P= 1.28 × 10−8 and P= 9.80 × 10−6 (pair-
wise LD metrics r2= 0.002, D’= 0.007)8. Furthermore, the
rs3781093 association is independent of the previously identiﬁed
10p14 association marked by rs2388486 (Supplementary Table 5);
respective conditional P-values are P= 3.38 × 10−8 and P=
1.32 × 10−12 (pairwise LD metrics r2= 0.002, D’= 0.27)7. For
NSHL we identiﬁed two new associations at 13q34 (rs112998813,
P= 4.58 × 10−8) and 16p13.13 (rs34972832, P= 2.12 × 10−8,
Table 1).
Relationship between the new risk SNPs and phenotype. A
hallmark of cHL epidemiology is the bimodal age-speciﬁc inci-
dence and it has been argued that the disease in young adults and
older adults is aetiologically different; in particular there is a low
prevalence of EBV-positive disease in NSHL patients aged
16–353. Case-only analysis did not provide evidence of sex dif-
ferences at newly identiﬁed risk SNPs (Supplementary Table 10)
or a relationship between age in the NSHL subgroup. Albeit not
signiﬁcant after correction for multiple testing, we observed an
association between EBV-positive disease and cHL at 6q23.3
in 796 cases analysed (rs6928977, P= 0.03, Supplementary
Table 10).
Biological inference. Five of the six new risk SNPs localise in or
near genes which have either been previously implicated in the
development of cHL or have established roles in B-cell develop-
ment and are therefore strong candidates for cHL susceptibility.
Speciﬁcally, the 6q22.33 association marked by rs9482849 maps
intergenically to THEMIS (thymocyte-expressed molecule
involved in selection) and PTPRK (receptor-type tyrosine protein
phosphatase kappa) (Fig. 1). Downregulation of PTPRK by the
EBV-encoded EBNA1 contributes to the growth and survival of
HRS cells13. The 6q23.3 association deﬁned by rs6928977 loca-
lises to intron 3 of AHI1 (abelson helper integration site-1)
(Fig. 1) which has been implicated in the development of both B-
and T-cell lymphoma14, 15. The 13q34 association marked by
rs112998813 is located in intron 5 of UPF3A (Fig. 1), a regulator
of nonsense transcripts16. The LD region of association also
harbours CDC16 (cell division cycle protein 16). CDC16, a sub-
unit of the anaphase-promoting complex17, targets cell cycle
regulatory proteins for proteasome degradation, thereby allowing
cell cycle progression, and is downregulated in HRS cells18. At
16p13.13, the rs34972832 association for NSHL maps to intron 18
of CLEC16A (C-type lectin domain family 1, Fig. 1) whose loss of
function affects both B-cell number and function19. The 10p14
association marked by rs3781093 maps intronic of GATA3
(Fig. 1). Transcriptional repression of GATA3 is essential for early
B-cell commitment, and aberrant GATA3 expression has been
observed in HRS cells20, 21. Intriguingly, the rs3781093 risk allele
for NSHL has previously been demonstrated to be protective for
paediatric B-cell acute lymphoblastic leukaemia (ALL)22.
To the extent that they have been deciphered, many GWAS
risk loci map to non-coding regions of the genome and inﬂuence
gene regulation. Hence, to gain insight into the biological
mechanisms for the associations of the newly identiﬁed risk
SNPs, we interrogated publicly accessible expression data on
lymphoblastoid cell lines (LCLs)23, 24. We used the summary
data-based Mendelian randomisation (SMR) analysis to test for
pleiotropy between GWAS signal and cis-expression quantitative
trait (eQTL) for genes within 1Mb of the sentinel SNP at each
locus to identify a causal relationship25. At 6q23.3 and 10p14,
signiﬁcant eQTLs were observed with AHI1 (PSMR= 8.63 × 10−6;
Supplementary Table 11 and Supplementary Fig. 5) and GATA3
(PSMR= 4.70 × 10−8; Supplementary Table 11 and Supplementary
Fig. 5).
Since spatial proximity between speciﬁc genomic regions and
chromatin looping interactions are central for the regulation of
gene expression, we identiﬁed patterns of chromatin interactions
at candidate causal SNPs by analysing promoter capture Hi-C
data on GM12878 as a source of B-cell information26. Looping
chromatin interactions were shown at 3q28 (rs4459895), 6q23.3
(rs6928977), 10p14 (rs3781093) and 16p13.13 (rs34972832).
While no signiﬁcant eQTL was shown for these chromatin
looping interactions they involved a number of genes with
biological relevance to cHL development (Fig. 1). At 3q28, the
looping interaction implicates BCL6 and mir-28, which have well
documented roles in B-cell tumour biology and GC B-cell
development27, 28. At 6q23.3, we observed interactions with
promoter sequences upstream in MYB and ALDH8A1. At 10p14,
both risk SNPs encompass a region that interacts with TAF3,
which encodes transcription initiation factor TFIID subunit 3.
TAF3 forms part of the transcription initiation factor TFIID and
is necessary for haematopoiesis29. Finally, we observed interac-
tions at the 16p13.13 risk locus with RMI2 (encoding RecQ
mediated genome instability 2) (Fig. 1). RMI2 is an essential
component of the Bloom helicase-double Holliday junction
dissolvasome and is responsible for genomic stability30.
Across the new and established risk loci for cHL we conﬁrmed
a signiﬁcant enrichment of DNase hypersensitivity in GM12878
cells (false discovery rate (FDR) adjusted P-value= 0.0035),
as well as enhancer elements in primary B-cells (FDR adjusted
P-value= 0.00064) and GM12878 cells (FDR adjusted
P-value= 0.015)31. Analysis of ChIP-seq data on 82 transcription
factors (TFs) showed an over-representation of the binding of TFs
that play a central role in B-cell signalling-networks such as RELA
(nuclear factor NF-kappa-B p65), EBF1 (early B-cell factor 1),
RUNX3 (runt-related transcription factor 3) and BATF (basic
leucine zipper transcription factor, ATF-like) (Fig. 2). Collec-
tively, these observations support the assertion that risk loci for
cHL mediate their effects through B-cell developmental networks,
and are strongly involved in transcriptional initiation and
enhancement.
The HLA region. To obtain additional insight into plausible
functional variants within the major histocompatibility region at
6p21, we imputed the classical HLA alleles, amino-acid residues
and SNPs using SNP2HLA32. To isolate independent associations
for NSHL and MCHL, we performed conditional step-wise
logistic regression on the strongest associated SNP, amino acid or
allele, until no further variants attained genome-wide signiﬁcance
(Fig. 3; Supplementary Table 12). For NSHL, we identiﬁed the
strongest association at rs9269081 (P= 1.74 × 10−39), which maps
within the class II HLA region, 3’of HLA-DRA. Additional class II
associations were shown by HLA-DPB1*03:01 (P= 3.35 × 10−17)
and Val86 in HLA-DRB1 (P= 3.52 × 10−13) (Fig. 3). In contrast,
the strongest association for MCHL was provided by rs1633096,
a class I HLA association 3’ of HLA-F (P= 2.72 × 10−23).
Additional class II associations for MCHL were observed at
rs13196329, located intronic of C6orf10 (P= 2.58 × 10−14) and
Val86 in HLA-DRB1 (P= 7.10 × 10−9) (Fig. 3).
Heritability of cHL. By ﬁtting all SNPs from GWAS simulta-
neously using Genome-wide Complex Trait Analysis33, the esti-
mated heritability of cHL, NSHL and MCHL attributable to all
common variation is 24.0% (±2.3%), 25.2% (±3.4%) and 21.9%
(±2.4%), respectively. This estimate represents the additive
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00320-1 ARTICLE
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Fig. 1 Regional plots of association results and recombination rates for the newly identiﬁed classical Hodgkin lymphoma (NSHL) risk loci. Results for a 3q28
(rs4459895) and nodular sclerosis Hodgkin lymphoma (NSHL) risk, b 6q22.33 (rs9482849) and classical Hodgkin lymphoma (cHL) risk, c 6q23.3
(rs6928977) and NSHL risk, d 10p14 (rs3781093) and NSHL risk, e 13q34 (rs112998813) and NSHL risk, and f 16p13.13 (rs34972832) and NSHL risk. Plots
show association results of both genotyped (triangles) and imputed (circles) single-nucleotide polymorphisms (SNPs) in the genome-wide association study
samples and recombination rates. −log10 P-values (y-axes) of the SNPs are shown according to their chromosomal positions (x-axes). The sentinel SNP in
each combined analysis is shown as a large circle or triangle and is labelled by its rsID. The colour intensity of each symbol reﬂects the extent of LD with the
top SNP, white (r2= 0) through to dark red (r2= 1.0). Genetic recombination rates, estimated using 1000 Genomes Project samples, are shown with a light
blue line. Physical positions are based on NCBI build 37 of the human genome. Also shown are the relative positions of genes and transcripts mapping to the
region of association. Genes have been redrawn to show their relative positions; therefore maps are not to physical scale. The middle track represents the
chromatin state segmentation track (ChromHMM) for lymphoblastoid cells using data from the HapMap ENCODE Project. The top track represents
capture Hi-C promoter contacts in GM12878 cells. The colour intensity of each contact reﬂects the interaction score
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variance, and therefore does not include the potential impact of
dominance effects or gene–environment interactions having an
impact on cHL risk. The currently identiﬁed non-HLA risk SNPs
thus only account for around 12% of the additive heritable risk.
Co-heritability with autoimmune disease. Although not uni-
versal, some epidemiological studies have reported associations
between cHL and various autoimmune diseases, raising the pos-
sibility of common genetic susceptibility and hence common
biological pathways34. Variation at a number of the cHL risk loci,
including 3p24.1, 5q31.1 and 6q23.3 has previously been impli-
cated as determinants of autoimmune disease risk supporting
such an assertion (Supplementary Data 1).
To investigate co-heritability globally between cHL and
autoimmune disease, we implemented cross-trait LD score
regression35. Using summary-level GWAS data we estimated
genetic correlations between cHL and six autoimmune diseases
curated by ImmunoBase; speciﬁcally rheumatoid arthritis36,
systemic lupus erythematosus37, multiple sclerosis (MS)38,
primary biliary cirrhosis39, ulcerative colitis (UC)40 and coeliac
disease41 GWAS data (Supplementary Table 13). We observed a
positive genetic correlation between cHL and MS (rg= 0.35,
P= 0.04) and a negative correlation between cHL and UC
(rg= −0.23, P= 0.01).
Discussion
To our knowledge, we have performed the largest GWAS of cHL
to date, identifying six new non-HLA risk loci. The availability of
comprehensive reference panels for the HLA region has allowed
us to delineate class I and class II associations for NSHL and
MCHL, substantiating recent documented differences between
these cHL histologies9.
Although functional analyses are required to determine the
biological basis of cHL association signals, we have demonstrated
that these risk loci are enriched for regulatory elements in B-cells.
Moreover, they feature an over-representation of key B-cell TF
binding, notably RELA, RUNX3, EBF1 and BATF. RELA is a TF
involved in NF-κB heterodimer formation. HRS cells show high
constitutive activity of NF-κB (both canonical and non-canonical
pathways)42, which promotes cell survival and growth through
inducing anti-apoptotic and pro-proliferative gene programs43, 44.
Inhibition of NF-κB in HRS cells leads to caspase-independent
apoptosis43. EBF1 cooperates with E2A and PAX5 to regulate
B-cell maturation45. Its expression in HRS cells is low46, which is
thought to contribute to the loss of normal B-cell phenotype47.
RUNX3 has important roles in B-cell maturation48 and down-
regulation of RUNX1 by RUNX3 is required for EBV-driven LCL
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growth49. BATF also appears to co-ordinate B-cell maturation50,
and is highly expressed in HRS cells51.
The strong HLA associations we identiﬁed for NSHL and
MCHL support recent observations for distinct class I and class II
relationships for these cHL subtypes9. Speciﬁcally, the class II
NSHL association marked by rs9269081 is in strong LD with the
previously identiﬁed risk SNP rs6903608 (r2= 0.92, D’= 1.0) for
EBV-negative NSHL9. For MCHL the class I association
rs1633096 shows correlation with the previously identiﬁed
marker SNP rs2734986 (pairwise r2 = 0.41, D’= 0.97) for
EBV-positive cHL9. A class I association for MCHL is consistent
with a high EBV positivity and supports the notion of defective
cytotoxic T-cell lymphocyte responses in EBV-infected HRS
cells52. Variation within the class II HLA region alters the risk of
autoimmune diseases53, but the underlying biological mechanism
of these associations has yet to be fully deﬁned. The class II HLA
association for NSHL and MCHL risk, comprising both coding
variants and non-coding SNPs, may explain the importance of
CD4+ T follicular helper (TFH) cells in cHL pathogenesis. In the
GC, there is a requirement for CD4+ TFH cells to interact with
GC B-cells through the T-cell antigen receptor (TCR) and HLA
class II proteins for normal plasma and memory cells forma-
tion54. It is therefore plausible that variation in peptide binding
and expression of the HLA class II proteins contributes to cHL
pathogenesis through interaction with CD4+ TFH cells. Such a
model is supported by the observation of variation at position
86 of HLA-DRB1 inﬂuencing TCR Vα gene expression55, the
predominance of CD4+ T-cells in cHL tumours56, the reliance of
HRS cells on the micro-environment for survival1, and the loss of
MHC class II expression on HRS cells57, the last of which is
associated with adverse prognosis. An alternative explanation for
the class II HLA association in cHL is the involvement of an
unidentiﬁed pathogen playing a causative role in cHL. Amino-
acid variants and SNPs within HLA-DRB1 modulate humoral
immune responses to common viruses, such as inﬂuenza A and
JC polyomavirus58. Consistent with such a model is dimorphic
variation at position 86 of HLA-DRB159, which we identify as
inﬂuencing risk of NSHL and MCHL, modulating the anchoring
pocket of the antigen binding site, and inﬂuencing the con-
formation of peptide–DR protein complexes while maintaining a
T-cell response60.
In our analysis we noted a reciprocal relationship between
NSHL risk and ALL risk at 10p14 (GATA3)22. Since GATA3
plays a key role in B-cell development and both ALL and NSHL
are malignancies derived from B-cells at different stages of
maturation, our observation leads to speculation of a signiﬁcant
temporal effect of genetic variation at this locus in response to an
environmental or mutational insult.
Although supported by a contemporaneous study and requir-
ing further validation61, we found evidence for common genetic
susceptibility between cHL and MS, thus raising the possibility of
shared environmental risk factors. A potential biological basis for
such a relationship may encompass aberrant immune activation
and cell proliferation.
In conclusion, our study provides further evidence for inher-
ited susceptibility to cHL and supports a model whereby risk loci
inﬂuence disease through effects on B-cell regulatory networks,
providing a mechanistic link between susceptibility and biology.
Our ﬁndings also emphasise the differences between the major
subtypes, which are reﬂective of differences in tumour aetiology.
Methods
Ethics. Collection of patient samples and associated clinico-pathological infor-
mation was undertaken with written informed consent. Relevant ethical review
boards approved the individual studies in accordance with the tenets of the
Declaration of Helsinki (UK-GWAS MREC 03/1/096, German-GWAS University
of Heidelberg 104/2004 and UK-GWAS-NSHLG MREC 09/MRE00/72). The
diagnosis of cHL (i.e., excluding cases with nodular lymphocyte predominant HL),
NSHL and MCHL (ICD-10-CM C81.1-3) in all cases was established in accordance
with World Health Organisation guidelines.
Genome-wide association studies. Primary study: We analysed constitutional
DNA from 1,717 cases ascertained through the NSHLG (http://www.public.ukcrn.
org.uk) from 2010 to 2013. These are detailed in Supplementary Table 1. Cases
were genotyped using the Illumina Oncoarray (Illumina Inc.). Controls which were
also genotyped using the oncoarray comprised: (1) 2,976 cancer-free men recruited
by the PRACTICAL Consortium—the UK Genetic Prostate Cancer Study
(UKGPCS) (age < 65 years), a study conducted through the Royal Marsden NHS
Foundation Trust and SEARCH (Study of Epidemiology & Risk Factors in Cancer),
recruited via GP practices in East Anglia (2003–2009), (2) 4,446 cancer-free women
from across the UK via the Breast Cancer Association Consortium (BCAC).
Published studies: We used GWAS data generated on two non-overlapping
case–control series of Northern European ancestry, which have been the subject of
previous analyses that are summarised in Supplementary Table 1. Brieﬂy: (1) The
UK-GWAS was based on 622 cases ascertained through the Royal Marsden
Hospital National Health Service Trust Family History study during 2004–20087,
and 5,677 controls from the UK Wellcome Trust Case Control Consortium 2
(WTCCC2)62. (2) The German-GWAS comprised 1,001 cases ascertained by the
German Hodgkin Study Group during 1998–20078, and 1,226 controls from the
Heinz Nixdorf Recall (HNR) study.
GWAS and meta-analysis. Standard quality control measures were applied to
each of the three GWAS (Supplementary Tables 2, 3 and 4)7, 8, 63. Speciﬁcally,
individuals with a low call rate (< 95%) as well as all individuals evaluated to be of
non-European ancestry (using the HapMap version III CEU, JPT/CHB and YRI
populations as a reference, Supplementary Fig. 1) were excluded. For apparent
ﬁrst-degree relative pairs, we excluded the control from a case–control pair or the
individual with the lower call rate. SNPs with a call rate < 95% were excluded as
were those with a MAF< 0.01 or displaying deviation from Hardy–Weinberg
equilibrium (HWE) (i.e., P< 10−6, Supplementary Table 4). GWAS data were
imputed to >10 million SNP with IMPUTE2 v2.364 software, using a merged
reference panel consisting of data from 1000 Genomes Project (phase 1 integrated
release 3, March 2012)11 and UK10K (ALSPAC, EGAS00001000090/
EGAD00001000195 and TwinsUK EGAS00001000108/EGAS00001000194 studies)
12. HLA imputation was conducted using SNP2HLA and the Type I Diabetes
Genetics Consortium reference panel of 5,225 individuals of European descent32.
The number of variants in the HLA imputation recovered with an information
measure of > 0.80 were 8,436 (94% of total variants), 8506 (95% of total variants)
and 8599 (96% of total variants) in the UK-GWAS, German-GWAS and UK-
NSHLG-GWAS data sets, respectively. Imputation was conducted separately for
each study, and in each, the data were pruned to a common set of SNPs between
cases and controls prior to imputation. Poorly imputed SNPs deﬁned by an
information measure <0.80 were excluded. Tests of association between SNPs and
cHL were performed using logistic regression under an additive genetic model in
SNPTESTv2.565. The adequacy of the case–control matching was evaluated using
Q–Q plots of test statistics (Supplementary Fig. 2). The inﬂation factor λ was based
on the 90% least-signiﬁcant SNP66. Where appropriate, principal components,
generated using common SNPs, were included in the analysis to limit the effects of
cryptic population stratiﬁcation that otherwise might cause inﬂation of test sta-
tistics. Eigenvectors for the GWAS data sets were inferred using smartpca (part of
EIGENSOFT) by merging cases and controls with Phase III HapMap samples. LD
metrics were calculated in vcftools v0.1.12b67, using UK10K merged 1000 Genomes
Project data and plotted using visPIG68.
Replication studies and technical validation. The eight SNPs in the most pro-
mising loci (Table 1; Supplementary Table 6), were taken forward for de novo
replication in an additional 1,284 cases from the NSHLG and 2,504 controls from
the UK replication 1 series (Supplementary Table 1). After this six SNPs were
genotyped in an additional replication series, (UK replication 2 series) comprising
953 cases and 565 controls from the Scotland and Newcastle Epidemiological Study
of Hodgkin Disease (SNEHD), the Young Adult Hodgkin Case–Control Study
(YHCCS) and the Epidemiology and Cancer Statistics Group Lymphoma
Case–Control Study (ELCCS; http://www.elccs.info) (Supplementary Table 1).
Full details of the SNEHD, YHCCS and ELCCS studies have been previously
reported69–71. Brieﬂy, SNEHD involved ascertainment of incident cases from
Scotland and Northern England during 1993–1997. YHCCS was based on newly
diagnosed cases aged 16–24 years from Northern England during 1991–1995.
ELCCS comprised cases residing in the north or parts of southwest of England aged
16–69 years with newly diagnosed, non-human immunodeﬁciency virus-related
cHL during 1998–2003. UK population controls matched to cases on age, sex and
area of residence were obtained from SNEHD, YHCCS and ELCCS. The
EBV status of cHL tumours in the UK replication 2 series was determined by
immunohistochemical staining for EBV latent membrane antigen-1 and/or EBV
EBV-encoded RNA in situ hybridisation using sections of parafﬁn-embedded
material72, 73.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00320-1
6 NATURE COMMUNICATIONS |8:  1892 |DOI: 10.1038/s41467-017-00320-1 |www.nature.com/naturecommunications
The ﬁdelity of GWAS imputation was assessed by the concordance between
imputed and directly genotyped SNP in a subset of samples (Supplementary
Table 7). Replication genotyping of UK samples was performed using competitive
allele-speciﬁc PCR KASP chemistry (LGC, Hertfordshire, UK). Primers, probes
and conditions are detailed in Supplementary Table 14. Call rates for SNP
genotypes were > 95% in each of the replication series. To ensure the quality of
genotyping in assays, at least two negative controls and a set of duplicates were
genotyped (concordance> 99%).
Meta-analysis. Meta-analyses were performed under a ﬁxed-effects model using
META v1.674. Cochran’s Q-statistic to test for heterogeneity and the I2 statistic to
quantify the proportion of the total variation due to heterogeneity were calculated;
an I2 value≥ 75% is considered to be characteristic of large heterogeneity75. We
used the test-based method of Higgins et al.76 to derive 95% CIs for I2 values
(Supplementary Table 9). To estimate study power of the discovery GWAS phase,
we made use of the CaTS online calculator77, assuming a risk allele frequency of 0.2
and genotype relative risk of 1.20.
Expression quantitative trait locus analysis. To examine the relationship
between SNP genotype and gene expression, we carried out SMR analysis as per
Zhu et al., 201625. Brieﬂy, if bxy is the effect size of x (gene expression) on y (slope
of y regressed on the genetic value of x), bzx is the effect of z on x, and bzy is the
effect of z on y. Therefore bxy (bzy/bzx) is the effect of x on y. To distinguish
pleiotropy from linkage where the top associated cis-eQTL is in LD with two causal
variants, one affecting gene expression the other affecting trait, we tested for het-
erogeneity in dependent instruments, using multiple SNPs in each cis-eQTL region.
Under the hypothesis of pleiotropy bxy values for SNPs in LD with the causal
variant will be identical. Thus testing against the null hypothesis that there is a
single causal variant is equivalent to testing heterogeneity in the bxy values esti-
mated for the SNPs in the cis-eQTL region. For each probe that passed signiﬁcance
threshold for the SMR test, we tested the heterogeneity in the bxy values estimated
for multiple SNPs in the cis-eQTL region using HEIDI.
We used publicly available LCL expression data from the MuTHER (n= 825)23
and GTEx consortium (n= 114)24. Brieﬂy, GWAS summary statistics ﬁles were
generated from the meta-analysis. Reference ﬁles were generated from merging
1000 Genomes Project phase 3 and UK10K (ALSPAC and TwinsUK) vcfs11, 12. As
previously advocated, only probes with at least one eQTL P-value of < 5.0 × 10−8
were considered for SMR analysis25. We set a threshold for the SMR test of
PSMR< 5.49 × 10−4 corresponding to a Bonferroni correction for 91 tests (91 probes
with a top eQTL P< 5.0 × 10−8 across the 12 loci and two LCL eQTL data sets).
For all genes passing this threshold, we generated plots of the eQTL and GWAS
associations at the locus, as well as plots of GWAS and eQTL effect sizes
(i.e., corresponding to input for the HEIDI heterogeneity test). HEIDI test P-values
< 0.05 were considered as being reﬂective of heterogeneity. This threshold is
conservative for gene discovery because it retains fewer genes than when correcting
for multiple testing. SMR plots for signiﬁcant eQTLs are shown in Supplementary
Fig. 5.
Chromatin state dynamics. Enrichment of cHL risk SNPs with DNAse and
enhancers is conducted using Haploreg v431. The overlap of cHL risk SNPs with
enhancers in GM12878 cell is compared to a background model of all 1000
Genomes Project variants with a frequency above 5% in any population. The
enrichment relative to these background frequencies was performed using a
binomial test and a FDR P-value was subsequently calculated; we considered an
FDR< 0.05 as being signiﬁcant.
To examine enrichment in speciﬁc TF binding across risk loci, we adapted the
variant set enrichment method of Cowper-Sal lari et al.78. For each risk locus,
a region of strong LD (deﬁned as r2> 0.8 and D′ > 0.8) was determined, and these
SNPs were termed the associated variant set (AVS). TF ChIP-seq uniform peak
data were obtained from ENCODE for the GM12878 cell line, and included data
for 82 TFs. For each of these marks, the overlap of the SNP in the AVS and the
binding sites was determined to produce a mapping tally. A null distribution was
produced by randomly selecting SNP with the same LD structure (generated from
1000 Genomes Project and UK10K data) as the risk associated SNP, and the null
mapping tally calculated. This process was repeated 10,000 times, and approximate
P-values were calculated as the proportion of permutations where the null mapping
tally was greater or equal to the AVS mapping tally. An enrichment score was
calculated by the tallies to the median of the null distribution. Thus the enrichment
score is the number of standard deviations of the AVS mapping tally from the
mean of the null distribution tallies.
Promoter capture Hi-C data. To map risk SNPs to interactions involving pro-
moter contacts and identify genes involved in cHL susceptibility, we analysed
promoter capture Hi-C data on the LCL cell line GM12878 as a model B-cell26.
Reads from technical replicates (E-MTAB-2323) were combined before processing
with HiCUP79. Signiﬁcant interactions (i.e., score≥ 5) on two biological replicates
were determined using CHiCAGO80.
Co-heritability of Hodgkin lymphoma with autoimmune disease. We utilised
LD regression to estimate genetic correlation between individual autoimmune
diseases and cHL, NSHL and MCHL35. Summary statistics for published studies of
coeliac disease41, systemic lupus erythematosus37, primary biliary cirrhosis39,
rheumatoid arthritis36, MS38 and UC40 were downloaded from the ImmunoBase
website (http://www.immunobase.org/).
Heritability analysis. We used genome-wide complex trait analysis to estimate the
polygenic variance (i.e., heritability) ascribable to all genotyped and imputed
GWAS SNPs33. SNPs were excluded based on low MAF < 0.01, poor imputation
(info score< 0.9) and evidence of departure from HWE (P< 0.05). Individuals
were excluded for poor imputation and where two individuals were closely related.
A genetic relationship matrix of pairs of samples was used as input for the
restricted maximum likelihood analysis to estimate the heritability explained by the
selected set of SNPs. To transform the estimated heritability to the liability scale, we
used the lifetime risk, for cHL, which is estimated to be 0.002 by SEER (https://seer.
cancer.gov/statfacts/html/hodg.html).
Data availability. Genotype data that support the ﬁndings of this study have been
deposited in the European Genome-phenome Archive (EGA) under accession
codes EGAD00000000022 and EGAD00000000024.
Sequencing data, which forms the reference panel for imputation, have been
deposited in the European Genome-phenome Archive (EGA) under accession
codes EGAS00001000090, EGAD00001000195, EGAS00001000108.
Transcriptional proﬁling data from the MuTHER consortium that support the
ﬁndings of this work have been deposited in the European Bioinformatics Institute
(Part of the European Molecular Biology Laboratory, EMBL-EBI) under accession
code E-TABM-1140.
Transcriptional proﬁling data from the Genotype-Tissue Expression (GTEx)
project, that support the ﬁndings of this work are available here: https://www.
gtexportal.org/
Transcription factor binding data that support the ﬁndings of this work are
available here: http://genome.ucsc.edu/ENCODE/downloads.html.
Promoter capture Hi-C data in GM12878 cells that support the ﬁndings of this
work have been deposited in the European Bioinformatics Institute (Part of the
European Molecular Biology Laboratory, EMBL-EBI) under accession code
E-MTAB-2323.
The remaining data contained within the paper and supplementary ﬁles are
available from the author upon request.
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